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The expression of class II determinants (Ia-like antigens) on human hemato- 
poietic progenitor cells (HPC) 1 cultured in semisolid medium, has been exten- 
sively studied for CFU-GM (colony-forming unit precursor of granulocyte/mac- 
rophage) (1), BFU-E (burst-forming unit of erythroid cells; the immature eryth- 
void committed progenitor cell) (1),  CFU-E (colony-forming unit of erythroid 
cells; the relatively mature erythroid committed progenitor cell) (1),  and CFU- 
GEMM  (colony-forming  unit  of granuiocyte/erythrocyte]macrophage/mega- 
karyocyte; the  multilineage  HPC)  (2).  With  both  polyclonai and  monoclonal 
antibodies (mAb), the expression of polymorphic and monomorphic HLA-DR 
determinants has been demonstrated on all  HPC,  using fluorescence-activated 
cell sorting (FACS) and complement-dependent cytotoxicity (CDC) assays (3-7), 
although  some conflicting results  have  been  published  (4,  5)  concerning the 
expression of HLA-DR determinants on CFU-E. On the other hand, HLA-DR- 
linked  HLA-DQ (DC,  MB,  LB)  determinants appear  not  to  be expressed on 
human HPC in semisolid cultures (7-9).  In mice, it has been reported (10,  11) 
that  the  pluripotentiai  stem  cell  CFU  of spleen  do  not  express  Ia  antigens. 
Actually, I-A antigens (equivalent to human HLA-DQ) seem not to be expressed 
on  CFU  of spleen,  whereas I-E antigens (equivalent to  human  HLA-DR) are 
(12). In dogs, no engraftment could be achieved after complete removal of Ia  + 
cells from autologous grafts (13). 
In man, there is no in vitro assay to determine the true pluripotent stem cell 
that is responsible for the hematopoietic reconstitution after transplantation of 
bone marrow cells into lethally irradiated recipients. However, from liquid long- 
term hematopoietic cell cultures,  HPC  can be cultured for many weeks (14). 
Thus,  in  this  long-term  culture  system, a  precursor  cell  responsible  for  the 
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sustained  proliferation  of committed  progenitor  cells  may  be  analyzed.  This 
precursor cell may be closely linked to the human true pluripotent stem cell. 
In such a  long-term culture  system, Moore et al. (16) could not identify class 
II determinants  on  HPC  responsible  for the  sustained  proliferation  of BFU-E 
and CFU-GM, although the precursor cell of CFU-GM appeared to express class 
II determinants.  However, other investigators (17) found inhibition of HPC in a 
similar long-term culture system after treatment with anti-HLA-DR and comple- 
ment.  Keating et  al.  (18)  could  not  detect  class  II  determinants  on  precursor 
cells responsible for the proliferation of CFU-GM in a different (one-stage) long- 
term  culture  system,  using  one  anti-class  II  antibody  in  a  CDC  assay,  but 
inconclusive  results were obtained  using another  class II antibody.  In all  these 
studies,  only depletion  techniques  were used to identify these antigens on HPC 
in long-term culture systems. Previously (19), we showed that,  using CDC assays 
only, antigenic  determinants  with  weak expression on  HPC can easily be over- 
looked. 
Here, we report the expression of HLA-DR determinants and the absence of 
HLA-DQ  determinants  on  precursor  cells responsible  for the  sustained  prolif- 
eration of CFU-GM, BFU-E, and CFU-GEMM in liquid long-term cultures, using 
both FACS and CDC assays. 
Materials and  Methods 
Collection and Preparation  of Bone Marrow  Cells.  Bone  marrow cells were obtained, 
after informed consent, by aspiration from the posterior iliac crests of donors for bone 
marrow transplantation,  and  were collected in  Hanks' balanced salt solution  with  100 
U/ml of preservative-free heparin. To establish stromal layers, red blood cells were lysed 
with an NH4CI buffer (0.155 M NH4CI, 0.01  M KHCO~, 0.1  mM EDTA, pH 7.4)for 10 
min at 0°C. The cell suspension was washed in RPMI  1640 with 5% fetal bovine serum 
(FBS)  (Gibco Laboratories, Grand  Island,  NY) at 0°C,  and resuspended  in a-modified 
Eagle's minimal essential medium (c~-MEM) (Flow Laboratories, Irvine, United Kingdom). 
For use in reinoculation, bone marrow cells were centrifuged over Ficoll-Isopaque (1.077 
g/cm  3,  1,000 g, 20 rain, 20°C), and the interphase was washed twice. These interphase 
cells were resuspended in a medium consisting of 70% RPMI  1640, 20% FBS, and  10% 
dimethylsulfoxide at 0°C.  The cell  suspensions  were  frozen  in  a  computer-controlled 
freezer at a rate of 1 °C/min from 0°C to -50°C, and at a rate of 4°C/rain from -50°C 
to -90°C. The cells were then stored in liquid nitrogen. Before reinoculation, the cells 
were thawed for 1 rain in a 37°C water bath, diluted in Hepes-buffered RPMI 1640 with 
20%  FBS at 0°C,  and washed twice in  the same medium at 0°C.  The cells were then 
treated  in  a  CDC  assay,  or  separated  using  cell  sorting  with  the  FACS  IV  (Becton- 
Dickinson  Immunocytochemistry Systems,  Sunnyvale,  CA),  and  reinoculated  on  the 
preestablished stromal layer. 
Liquid  Long-term Cultures (15).  107 bone marrow cells collected after red blood cell 
lysis were  cultured  in  a  fully humidified atmosphere of 33°C  and  5%  CO2,  in  plastic 
culture flasks in  10 ml of medium consisting of Hepes-buffered c~-MEM, with 25% fresh 
(frozen) ABO-compatible human heparin plasma and  10  -6 M hydrocortisone. Once per 
week, half of the nonadherent cell  suspension was removed, and 5 ml of fresh medium 
was added. After 4-5 wk, a stromal layer was established. 
After treatment of cryopreserved autologous bone marrow mononuclear cells in a CDC 
assay or using FACS, these cells were inoculated on the preestablished stromal layers. The 
suspension of the day of reinoculation was called week 0. From weeks 1-6 after reinocu- 
lation,  the  nonadherent  suspensions  were  demipopulated  weekly,  and  5  ml  of fresh 
medium was added. The harvested cell suspension was cultured for CFU-GM (defined as 
aggregates of >20 granulocytic, monocytic, or eosinophilic cells), BFU-E (defined as bursts FALKENBURG ET  AL.  1361 
of colonies consisting of hemoglobinized cells), and  CFU-GEMM  (defined  as  colonies 
containing at least both erythroid and myeloid cells (2, 7), in a medium consisting of 30% 
fresh (frozen) ABO-compatible human heparin plasma,  7.5% phytohemagglutinin-stimu- 
lated  leukocyte-conditioned medium,  5%  10  -3  M  2-mercaptoethanol,  5%  deionized 
bovine serum albumin, 5% human transferrin, 5% Iscove's modified Dulbecco's medium, 
1  U/ml  erythropoietin  (2.5%),  and  40%  methylcellulose  2.8%  (at  37°C,  in  a  fully 
humidified atmosphere with 5% CO2). The numbers of HPC were counted on days 14- 
18. 
Antibodies.  mAb B8.11.2 (Malissen,  Marseille,  France) an IgG2b antibody exclusively 
reactive with HLA-DR molecules and not reactive with HLA-DQ determinants, was used 
in both CDC and in cell-sorting experiments. In CDC, the anti-DQwl antibody IIB.3, an 
IgG2b antibody  (F.  Koning,  Leiden,  The  Netherlands)  was  used,  and  in  cell-sorting 
experiments, the anti-DQwl antibody, Genox 3.53, an IgG1 antibody (Bodmer, London, 
United Kingdom) was used. Anti-DQwl antibodies were used only against bone marrow 
cells of DQwl  ÷ donors. All  B cells of the DQwl  ÷ donors strongly reacted with the anti- 
DQwl antibodies (data not shown).  All antibodies were used as diluted ascites (1:100). 
Complement-dependent Cytotoxicity.  107 cryopreserved mononuclear bone marrow cells 
in  1 ml medium were incubated with an equal volume of mAb for 1 h at  20°C. Baby 
rabbit complement (prescreened  batches) (Pel-Freez Biologicals,  Rogers, AR) was then 
added to a  final  concentration of 20% in case  of anti-HLA-DR antibodies, and 40%  in 
case  of anti-HLA-DQwl antibodies,  which  had  been  proven  (7,  19)  to  be  the  highest 
complement concentration that was intrinsically  nontoxic. After another 1-h incubation 
at 20°C, the cells were washed three times in  RPMI  1640 plus 5% FBS, resuspended in 
a-MEM, and inoculated on the preestablished autologous stromal layers. As a control, 107 
cells were incubated with antibody only, and reinoculated on an autologous stromal layer. 
Fluorescence-activated Cell Sorting.  Cryopreserved mononuclear cells at a concentration 
of 107 ce|ls/ml  were  incubated  with equal  volumes of antibody for  1 h  at  20°C, and 
washed three times in RPMI 1640 plus 5% FBS. Cells were then reincubated for 30 min 
at  20°C  with  fluorescein  isothiocyanate  (FITC)-Iabeled  goat  anti-mouse  Ig  (Nordic 
Immunology, Tilburg,  the  Netherlands),  and  washed  twice.  3-10  ×  106  cells  were 
separated into a  negative and a  positive fraction using the Becton-Dickinson FACS-IV. 
For HLA-DR antibodies, the cut-off point was chosen at fluorescence intensity channel 
120 (logarithmic scale). After incubation with irrelevant control antibodies, no HPC could 
be recovered from the positive channels  121-255. For HLA-DQ antibodies, the cut-off 
point was  chosen at  channel  60.  After incubation  of the  cells  with  irrelevant  control 
antibodies, >95% of the  HPC were recovered from the negative fraction (channels  1- 
60).  After sorting, the positive and negative fractions were inoculated on preestablished 
autologous  stromal  layers.  As  a  control,  an  equal  number  of unseparated  cells  was 
reinoculated on an autologous stromal layer, thus determining the 100% growth value. 
Calculations.  In Figs.  1 and 3, the numbers of HPC are shown, corrected for demi- 
population after  week  1.  In  Figs.  2,  4,  and  5,  and  in  Table  1,  the  numbers  of HPC 
cultured from the treated fractions from weeks 0-6 after reinoculation were expressed as 
percentage of the numbers of HPC cultured from the control suspension at that particular 
week. 
The regeneration index was calculated by dividing the total number of HPC, corrected 
for demipopulation, obtained after reinoculation in weeks  1-6, by the number of HPC in 
the reinoculated suspension (week 0). 
In Table I I, the cumulative numbers of H PC after reinoculation (weeks 1-6) per treated 
fraction are expressed as percentage of the cumulative numbers of HPC cultured from 
the control suspensions (weeks  1-6), and compared with the numbers of HPC cultured 
from the reinoculated suspensions (week 0). 1362  HLA-DR  ANTIGENS  ON  STEM  CELLS  IN  LONG-TERM  CULTURES 
Results 
The regeneration  index was 2.38 +  0.26 for CFU-GM,  !.00 +  0.12 for BFU- 
E, and  1.87  ±  0.34  for CFU-GEMM  (mean  ±  SE;  18  experiments),  indicating 
sustained proliferation of HPC after reinoculation. 
As shown in  Fig.  1, elimination of nearly all proliferating  HPC after reinocu- 
lation  was observed after  treatment  of the  bone  marrow  cell  suspension  with 
anti-HLA-DR  antibodies and  complement  before  reinoculation.  There  was no 
inhibition of proliferation of HPC after incubation with antibody or complement 
only  (data  not shown).  Fig.  2  shows that,  although  anti-DR  antibodies  almost 
completely  abolished  the generation  of HPC after reinoculation,  treatment  of 
the bone marrow cells with anti-HLA-DQwl antibody IIB.3 and 40% complement 
before reinoculation did not result in a significant decrease in HPC proliferation. 
We used the highest complement  concentration  that was intrinsically  nontoxic 
to show that  HLA-DQ  antigens  are  not expressed  on these  HPC,  since  it  has 
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FICURE  1.  Recovery of proliferated HPC, corrected  for demipopulation, after reinoculation 
of 107 cryopreserved autologous mononuctear bone marrow cells, treated with anti-HLA-DR, 
with or without addition of complement to a final concentration of 20%. Areas indicate mean 
+_ SE of six experiments, f-l, anti-DR antibody only, I~, anti-DR plus complement. 
c  .£ 












'"  '"  tt t 
1  2  3  4  5  6 
Weeks after  reinoculation 
FIGURE  2.  Inhibition  of proliferated  CFU-GM  (O  and  0),  BFU-E  (O  and  e),  and  CFU- 
GEMM  (E] and III), after  treatment  of the  reinoculated  cell  suspension  with anti-HLA-DQ 
(open symbols; n  =  4) and 40% baby rabbit complement (prescreened,  intrinsically nontoxic), 
or with anti-HLA-DR (filled symbols; n =  6) and 20% complement, as compared to the control 
suspension, incubated with the antibody only. Bars indicate mean +  SE. FALKENBURG  ET  AL.  1363 
been shown (19) that antigens with low density on HPC can easily be overlooked 
when low complement concentrations are used in CDC assays. As shown in Fig. 
3, after separation of the reinoculum into HLA-DR  + and HLA-DR- fractions, 
using B8.11.2 mAb and cell sorting, the majority ofCFU-GM, BFU-E, and CFU- 
GEMM  were  recovered  from the  HLA-DR  + fractions during the  6  wk after 
reinoculation.  <20%  of the  HPC  could  be  recovered  from  the  HLA-DR- 
reinoculum, as compared to the unseparated controls per week after reinocula- 
tion (Fig. 4).  As shown in Fig. 5, hardly any HPC could be recovered from the 
HLA-DQwl  + fractions after reinoculation of mononuclear bone  marrow  cells 
from HLA-DQwl  + donors after cell sorting using the anti-HLA-DQwl antibody, 
Genox 3.53. 
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FIGURE  3.  Recovery of proliferated hematopoietic progenitor cells, corrected for demipop- 
ulation, after reinoculation of 3 x  10  6 cryopreserved autologous mononuclear hone marrow 
cells, separated  into an  HLA-DR  + and an  HLA-DR-  fraction, using FACS.  Areas indicate 
mean +- SE of five experiments. F-I, DR- fraction; I~, DR + fraction. 
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FIGURE 4.  Recovery of proliferated CFU-GM (O and O), BFU-E (O and e), and CFU-GEMM 
(I-I and II) after cell sorting using anti-HLA-DR. Filled symbols represent the percentages of 
HPC in the positive fractions; open symbols those in the negative fractions, as compared to 
the unseparated control of that week. Bars indicate mean +- SE of five experiments, in case of 
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FIGURE 5.  Recovery of proliferated CFU-GM (© and O), BFU-E (O and O), and CFU-GEMM 
([] and II) after cell sorting,  using anti-HLA-DQwl and bone marrow cells of HLA-DQwl  ÷ 
donors.  Filled symbols represent  the  percentages  of HPC in  the  positive fractions; open 
symbols those in the negative fractions, as compared to the unseparated control of that week. 
Bars indicate mean +  SE of three experiments.  Symbols with "1" superscript  indicate one 
experiment;  in the two other experiments, HPC from week 4 were destroyed by infection of 
the semisolid cultures. 
To avoid the possibility that nonspecific differences in antibody binding would 
be responsible for these findings, the HLA-DR  + fraction was defined as strongly 
positive  fluorescence  intensity  (channels  121-255).  In  case  of HLA-DQ  anti- 
bodies, the HLA-DQ  + fraction was defined as channels 61-255. When mAb with 
irrelevant specificity or the secondary FITC-labeled antibodies only were used, 
no HPC could be recovered from channels  121-255.  No substantial  difference 
in  HPC  recovery from the  negative (channels  1-60)  or  positive (channels  61- 
255) fractions were found, no matter whether HLA-DQ antibodies or irrelevant 
control antibodies were used (data not shown). 
To exclude the possibility that, in cell sorting experiments, HLA-DR  + accessory 
cells present in the reinoculated bone marrow might have activated residual HPC 
present  in  the  stromal layer before reinoculation,  so that  the  HPC responsible 
for  the  proliferation  after  reinoculation  were  not  actually  obtained  from  the 
HLA-DR  + fraction, we performed the celt sorting experiment described in Table 
I.  Irradiation of the  stromal  layer with  3,000  tad before reinoculation  did  not 
affect the  proliferation of HPC in  the  HLA-DR  + and  HLA-DR- fractions,  nor 
in the unseparated control as compared to the nonirradiated control. Therefore, 
we conclude  that  the  HPC  responsible  for the  sustained  proliferation  of CFU- 
GM,  BFU-E,  and  CFU-GEMM  originated  from  the  reinoculated  HLA-DR  + 
fraction. 
In Table II, the cumulative numbers of class II-positive HPC recovered after 
reinoculation,  expressed as percentages  of the  cumulative numbers of HPC in 
the  control  suspension,  are compared  with  the  percentages of class  II-positive 
HPC in the suspension at the time of reinoculation.  Using both FACS and CDC, 
the  vast  majority of HPC  appeared  to  be  HLA-DR  +  and  HLA-DR-.  In  fact, 
there were no substantial differences beween the percentages of class II-positive FALKENBURG  ET  AL.  1365 
TABLE  I 
Influence  of lrradiation of Stromal Layer on Recovery of HPC Reinoculated  after FACS 
Separation  of Bone Marrow Cells into HLA-DR  + and HLA-DR- Fractions 
Absolute numbers of HPC (corrected for demipopulation) 
Unseparated con- 
HPC  Week  Not reinoculated  HLA-DR-  HLA-DR  +  trol 
Unirra-  lrradi-  Unirra-  Irradi-  Unirra-  Irradi-  Unirra-  Irradi- 
diated  ated*  diated  ated*  diated  ated*  diated  ated* 
CFU-GM  1  104  0  127  209  1,346  1,573  2,784  3,328 
2  86  0  465  434  2,789  3,292  4,389  3,912 
3  231  0  1,260  856  1,389  884  2,081  2,677 
4  139  0  533  167  1,986  4,053  3,714  3,048 
5  375  0  483  150  1,815  3,123  2,627  3,079 
6  0  0  0  0  0  0  0  0 
Total(weeks 1-6)  935  0  2,868  1,816  9,325  12,925  15,595  16,044 
1  92  0  87  127  711  637  2,007  1,741 
2  86  0  416  233  1,357  1,314  2,640  2,433 
3  33  0  285  342  245  397  425  586 
4  139  0  164  268  917  1,004  890  1,151 
5  0  0  138  75  435  213  438  80 
6  0  0  0  0  0  0  0  0 
Total(weeks 1-6)  350  0  1,090  1,045  3,665  3,565  6,400  5,991 
CFU-GEMM  1  46  0  51  31  292  353  735  666 
2  37  0  167  124  996  945  1,445  1,101 
3  66  0  346  86  245  137  446  418 
4  0  0  164  33  343  557  817  677 
5  0  0  70  75  218  284  438  163 
6  0  0  0  0  0  0  0  0 
Total (weeks 1-6)  149  0  798  349  2,094  2,276  3,881  3,025 
6  x  106  mononuclear bone marrow cells were separated into an  HLA-DR- and an  HLA-DR  + 
fraction,  using  FACS (61%  and  39%,  respectively). Half of the sorted cells per  fraction were 
reinoculated on  an  irradiated autologous stromal layer, and the other half on an  unirradiated 
stromal layer. As a control, 3  ×  106 unseparated cells were reinoculated on an irradiated stromal 
layer, and an equal number on an unirradiated stromal layer. 
* Stromal layers were irradiated with 3,000 rad immediately before reinoculation. 
HPC responsible for the sustained proliferation of HPC in  long-term cultures 
and the percentages of class  II-positive HPC cultured from the bone marrow 
suspension in semisolid medium before reinoculation. In the FACS experiments, 
the cut-off point was chosen at channel 120 to select only clearly positive cells, 
resulting in the allocation of up to 20%  of HPC to the negative fraction. The 
regeneration indices of the negative and clearly HLA-DR  ÷ fractions were similar, 
indicating that the  HPC  in  the  HLA-DR- fraction did not have an  increased 
proliferation potential as compared to the HLA-DR  + fraction. 
Discussion 
Using CDC, our data clearly show that proliferation of HPC after reinoculation 
can be abolished by treatment of the bone marrow cells with anti-HLA-DR and 1366  HLA-DR  ANTIGENS  ON  STEM  CELLS  IN  LONG-TERM  CULTURES 
TABLE  II 
Comparison of Class H Expression on HPC Present in Bone Marrow at Time of Reinoculation 
with Class II Expression on HPC Responsible  for Proliferation after Reinoculation 
HPC subtype 
HPC per fraction after separation (percentage of 
unseparated control)  Percent inhibition of CDC 
DR  +  DR-  DQ  ÷  DQ-  Anti-DR +  C  Anti-DQ +  C 
(n--5)  (n=5)  (n=3)  (n=3)  (20%)(n=6)  (40%)(n=4) 
Present at time 
of reinocula- 
tion 
CFU-GM  68"-.15"  11"-.4  5"--5  91"-.16  92+4  29--.13 
BFU-E  72+-  12  13-4  2+-  1  82-+  12  92+6  22+-  10 








62+13  12-----5  7"--7  71"-.23  91"-.4  9+14 
76"-.18  9"--3  4"--5  90"-.31  93+4  10"-.18 
58"--9  9"--4  7"--8  80+29  92"--3  22"-.19 
* Mean +  SE. 
complement before reinoculation (Figs.  1 and 2). Although these results indicate 
that the precursor cells  responsible for the sustained proliferation of HPC are 
HLA-DR  +,  this phenomenon might also be  explained by elimination of rein- 
oculated HLA-DR  + accessory cells  required for the proliferation of HPC.  To 
exclude this possibility, FACS experiments were performed. After incubation of 
the bone marrow cells with anti-HLA-DR, the suspension was separated into an 
HLA-DR- and HLA-DR  + fraction, and reinoculated. The vast majority of the 
proliferated CFU-GM, BFU-E, and CFU-GEMM were cultured from the HLA- 
DR  + fractions after reinoculation (Figs.  3 and 4), demonstrating that the precur- 
sor  cells  recovered  from  the  reinoculated  suspensions  express  the  HLA-DR 
determinants themselves. 
To further exclude the possibility that the proliferation of HPC after reinoc- 
ulation was due to activation of residual HPC in the stromal layer by HLA-DR  + 
accessory cells from the sorted DR  + fraction, the previously established stromal 
layer was irradiated before reinoculation. Since this irradiation did not influence 
the results (Table I), the precursor cells responsible for the maintenance of HPC 
growth  after  reinoculation  must  have  been  recovered  from  the  HLA-DR  + 
fraction. Therefore, these precursor cells were HLA-DR  + themselves. 
On  the  other  hand,  anti-HLA-DQ  antibodies,  which  are  directed  against 
another  class  II  determinant closely  linked  to  HLA-DR,  did  not  react  with 
precursor cells  responsible for the proliferation of HPC in long-term cultures, 
neither in  CDC  nor in  FACS assays (Figs.  2  and  5).  Thus,  our results clearly 
indicate that not only the HPC capable of differentiating into mature blood cells 
(week 0 HPC) are HLA-DR  + and HLA-DQ-, but also that the HPC responsible 
for the sustained proliferation of CFU-GM,  BFU-E, and CFU-GEMM in vitro 
express HLA-DR determinants, and lack DQ antigens. FALKENBURG ET AL.  1367 
Although similar results have been preliminarily reported by some investiga- 
tors (I 7),  others (16,  18) have reported that the capacity of bone marrow cells 
to produce HPC in long-term culture systems after treatment of the (re)inoculum 
with anti-HLA-DR and complement was not significantly reduced. Therefore, 
we investigated whether precursor cells with no, or only low HLA-DR expression 
were capable of producing relatively more HPC after reinoculation than HLA- 
DR  + precursor cells. As shown in Table II, there appeared to be no differences 
in proliferation potential between HPC with low HLA-DR expression and HPC 
with high HLA-DR expression. 
Based on these findings and the conflicting results of other investigators (4, 5, 
19), we hypothesize that, although (almost) all HPC capable of in vitro prolifer- 
ation and differentiation appear to be HLA-DR +, the degree of expression may 
differ considerably. The percentages of HLA-DR  ÷ HPC found may therefore 
depend on the sensitivity of the assay used, and may be influenced by differences 
in experimental conditions, such as differences in anti-class II antibodies, and 
complement sources or concentrations (19). 
We hypothesize further that, since it has been shown (5, 21) that at least part 
of the regulation of hematopoiesis is strongly associated with HLA-DR expres- 
sion, the degree of expression of class II molecules on HPC may be an important 
factor in  the regulation  of hematopoiesis.  The  more HLA-DR  molecules are 
expressed on HPC, the more these HPC may be subject to regulatory humoral 
and cellular agents (21). 
Our results open the possibility of studying class  II-associated regulation of 
HPC proliferation in liquid long-term cultures. Furthermore, because HLA-DQ 
antigens are not expressed on HPC,  HLA-DQ  + neoplastic cells (e.g. mature B 
cell tymphomas; 22) can be removed from autologous bone marrow grafts using 
anti-HLA-DQ antibodies.  Alternatively, if the human true pluripotential stem 
cells express HLA-DR antigens, positive selection of stem cells for bone marrow 
transplantation may be achieved using anti-HLA-DR antibodies. 
Summary 
The expression of HLA-DR antigenic determinants on human hematopoietic 
progenitor  cells  (HPC)  capable  of differentiating into  mature  blood  cells,  as 
determined in semisolid cultures, has been demonstrated previously (3-7). Here, 
we investigated the expression of class  II determinants on HPC responsible for 
the sustained proliferation of colony-forming units of granulocyte/macrophage 
(CFU-GM),  of multilineage HPC  (CFU-GEMM,  granulocyte/erythrocyte/mac- 
rophage/megakaryocyte), and burst-forming units of erythroid cells (BFU-E) in 
liquid  long-term  cultures.  Using  both  fluorescence-activated cell  sorting  and 
complement-dependent cytotoxicity  assays,  HLA-DR  determinants  could  be 
identified  on  virtually  all  these  HPC  capable  of  proliferating  in  long-term 
cultures. Experiments in which the stromal layer had been irradiated provided 
evidence that the HPC themselves were truly HLA-DR  +, and that the sustained 
proliferation of HPC was not due to activation of HLA-DR- residual HPC  in 
the stromal layer by reinoculated HLA-DR  + accessory cells. Furthermore, it was 
shown that all HPC recognized in semisolid and liquid long-term cultures were 
HLA-DQ-. These results suggest that the human true pluripotential stem cell is 1368  HLA-DR  ANTIGENS ON  STEM  CELLS  IN  LONG-TERM  CULTURES 
HLA-DR  +.  These  results  open  the  possibility  of studying  class  II-dependent 
regulation of hematopoiesis in liquid long-term cultures. 
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